Array BioPharma Grants InterMune Expanded Rights Under Hepatitis C Discovery Agreement

Article

BOULDER, Colo. -- Array BioPharma Inc. announced that it has expanded the intellectual property rights granted to InterMune, Inc. relating to certain compounds discovered under their existing hepatitis C (HCV) drug discovery collaboration agreement that was established in September 2002.  Array will receive a one-time payment of $2,500,000 from InterMune in exchange for these expanded rights.  All other economic terms under this agreement remain unchanged.

In addition, under the terms of a new agreement, Array has granted InterMune an exclusive option through March 31, 2005 to access Arrays small molecule drug discovery platform for targets of interest to InterMune in hepatology.  Should InterMune select a new target, Array would be entitled to receive research funding as well as potential future milestone payments and royalties under this second collaboration.

Source: Array BioPharma Inc.

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content